Edition:
India

AC Immune SA (ACIU.OQ)

ACIU.OQ on NASDAQ Stock Exchange Global Market

11.37USD
22 Nov 2017
Change (% chg)

$-0.36 (-3.07%)
Prev Close
$11.73
Open
$11.50
Day's High
$11.81
Day's Low
$11.33
Volume
22,311
Avg. Vol
23,158
52-wk High
$15.00
52-wk Low
$6.24

Chart for

About

AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson's, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology... (more)

Overall

Beta: --
Market Cap(Mil.): $639.40
Shares Outstanding(Mil.): 56.77
Dividend: --
Yield (%): --

Financials

BRIEF-AC Immune SA reports quarterly ‍loss per share CHF 0.15

* AC Immune SA reports third quarter 2017 financial results and corporate update

13 Nov 2017

BRIEF-AC Immune SA to receive milestone payment for anti-tau antibody moving into phase 2 trial for alzheimer's disease

* AC Immune SA to receive milestone payment for anti-tau antibody moving into phase 2 trial for Alzheimer's Disease

02 Nov 2017

BRIEF-AC Immune to get milestone payment for Alzheimer drug

* Says to receive milestone payment for anti-tau antibody moving into phase 2 trial for Alzheimer's disease ‍​

02 Nov 2017

BRIEF-AC Immune to present at two investor conferences and provide scientific updates at CTAD conference

* AC Immune to present at two investor conferences and provide scientific updates at CTAD conference Source text for Eikon: Further company coverage:

24 Oct 2017

BRIEF-AC Immune completes recruitment for low-dose cohort in world's first clinical trial for Anti-Abeta Vaccine

* AC Immune completes recruitment for low-dose Cohort in world's first clinical trial for Anti-Abeta Vaccine targeting alzheimer's disease-like characteristics in individuals with down syndrome Source text for Eikon: Further company coverage:

12 Sep 2017

BRIEF-AC Immune reports Q2 ‍loss per share CHF 0.22​

* Q2 earnings per share view chf -0.16 -- Thomson Reuters I/B/E/S

09 Aug 2017

Earnings vs. Estimates